An Information Portal to 108263 Biological Macromolecular Structures

CWB is found in 1 entries
  •   Chemical Component Summary   Hide
    Name 1-methyl-N-[(1R,5S)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl]indazole-3-carboxamide
    Identifiers 1-methyl-N-[(3-endo)-9-methyl-9-azabicyclo[3.3.1]non-3-yl]-1H-indazole-3-carboxamide
    Synonyms GRANISETRON
    Formula C18 H24 N4 O
    Molecular Weight 312.41 g/mol
    Type non-polymer
    Isomeric SMILES
  •   Drug Info: DrugBank Hide
    DrugBank ID DB00889   (Different stereochemistry)
    Name Granisetron
    • approved
    • investigational
    Description A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. [PubChem]
    • BRL-43694
    • Granisetron
    • Granisetronum
    • Sancuso
    • SID90340785
    Salts Granisetron Hydrochloride
    Brand names
    • Granisetron
    • Granisetron Hydrochloride
    • Sancuso
    Affected organism Humans and other mammals
    Indication For the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy (including high dose cisplatin), postoperation, and radiation (including total body irradiation and daily fractionated abdominal radiation).
    Pharmacology Granisetron is a selective inhibitor of type 3 serotonergic (5-HT3) receptors. Granisetron has little or no affinity for other serotonin receptors, including 5-HT 1 , 5-HT 1A , 5-HT 1B/C , or 5-HT 2 ; for alpha 1 -, alpha 2 -, or beta-adrenoreceptors; for dopamine D 2 receptors; for histamine H 1 receptors; for benzodiazepine receptors; for picrotoxin receptors; or for opioid receptors. In most human studies, granisetron has had little effect on blood pressure, heart rate, or electrocardiogram (ECG). The drug is structurally and pharmacologically related to ondansetron, another selective inhibitor of 5-HT3 receptors. The serontonin 5-HT3 receptors are located on the nerve terminals of the vagus in the periphery, and centrally in the chemoreceptor trigger zone of the area postrema. The temporal relationship between the emetogenic action of emetogenic drugs and the release of serotonin, as well as the efficacy of antiemetic agents suggest that chemotherapeutic agents release serotonin from the enterochromaffin cells of the small intestine by causing degenerative changes in the GI tract. The serotonin then stimulates the vagal and splanchnic nerve receptors that project to the medullary vomiting center, as well as the 5-HT3 receptors in the area postrema, thus initiating the vomiting reflex, causing nausea and vomiting.
    Mechanism of action Granisetron is a potent, selective antagonist of 5-HT3 receptors. The antiemetic activity of the drug is brought about through the inhibition of 5-HT3 receptors present both centrally (medullary chemoreceptor zone) and peripherally (GI tract). This inhibition of 5-HT3 receptors in turn inhibits the visceral afferent stimulation of the vomiting center, likely indirectly at the level of the area postrema, as well as through direct inhibition of serotonin activity within the area postrema and the chemoreceptor trigger zone.
    Route of administration
    • intravenous
    • oral
    • transdermal
    • Serotonin Antagonists
    • Antiemetics
    ATC-Code A04AA02
    AHFS-Code 56:22.20
    CAS number 109889-09-0
    Name Sequence search Pharmacological action Actions
    5-hydroxytryptamine receptor 3A   Search  yes antagonist
    5-hydroxytryptamine receptor 3A   Search  yes antagonist
Ligand Image